Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. Issue 1 (15th December 2019)

• Record Type: Journal Article
• Authors: Khanna, Saira; Komati, Rahul; Eichenbaum, David A; Hariprasad, Ishani; Ciulla, Thomas A; Hariprasad, Seenu M
• Is Part Of: BMJ open ophthalmology. Volume 4:Issue 1(2019)
• Publication Date: 2019-12-15
• Subjects: Retina -- Macula -- Treatment Medical; Ophthalmology -- Periodicals; 617.7005
• DOI: 10.1136/bmjophth-2019-000398
• Languages: English
• ISSNs: 2397-3269

Abstract

Abstract : Age-related macular degeneration is the leading cause of vision loss in the developed world, with the expected number of affected elderly individuals reaching 17.8 million. Antivascular endothelial growth factor (anti-VEGF) injection therapy has been instrumental in treating a disease process that was previously thought to be untreatable. Over the past two decades, landmark studies have demonstrated the efficacy of different anti-VEGF medications and investigated the optimal dosing regimen and delivery mechanism to increase overall vision and minimise patient burden. In this review, we outline landmark neovascular age-related macular degeneration clinical trials that have demonstrated level 1 evidence for its usage or have contributed to the understanding of how to dose these agents.